Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06004128
NCT06004128No Longer AvailableNot Applicable

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

Invivyd, Inc.0 sitesStarted: August 22, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
No Longer Available
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

No Longer Available
Not Applicable
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)Multiple Myeloma
NCT05238311Pfizer
Available
Not Applicable
Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.Colitis, Ulcerative
NCT06025227Pfizer
Available
Not Applicable
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Metastatic Castration-Resistant Prostate Cancer
NCT05650476Pfizer
Available
Not Applicable
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)Alopecia Areata
NCT05522556Pfizer
Available
Not Applicable
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 MutationAdvanced Non-small Cell Lung CancerCancer
NCT06761976Bayer